Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher D Byrne

Showing results (11-20 of 458) with videos related to

Pageof 46
Sort By:
The Journal of Clinical Endocrinology and Metabolism|January 8, 2013
Clinical Review: Nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complicationsGiovanni Targher, Christopher D Byrne
Nature Reviews. Gastroenterology & Hepatology|June 30, 2016
Obesity: Metabolically healthy obesity and NAFLDGiovanni Targher, Christopher D Byrne
Endocrine|March 6, 2014
Lower 25-hydroxyvitamin D3 levels and increased risk of liver diseases: is there a causal link?Giovanni Targher, Christopher D Byrne
Metabolic Syndrome and Related Disorders|February 26, 2015
A Perspective on Metabolic Syndrome and Nonalcoholic Fatty Liver DiseaseGiovanni Targher, Christopher D Byrne
Hepatology (Baltimore, Md.)|August 3, 2018
Ad Libitum Mediterranean or Low-Fat Diets as Treatments for Nonalcoholic Fatty Liver Disease?Giovanni Targher, Christopher D Byrne
ACP Journal Club|January 20, 2005
Review: orlistat and sibutramine are modestly effective for weight loss at 1 yearChristopher D Byrne, Sarah Wild
Heart (British Cardiac Society)|May 16, 2008
Time to rethink high-density lipoprotein?Sarah Wild, Christopher D Byrne
Seminars in Thrombosis and Hemostasis|February 12, 2013
Diagnosis and management of nonalcoholic fatty liver disease and its hemostatic/thrombotic and vascular complicationsGiovanni Targher, Christopher D Byrne
Nature Reviews. Gastroenterology & Hepatology|November 20, 2019
What's new in NAFLD pathogenesis, biomarkers and treatment?Christopher D Byrne, Giovanni Targher
Arteriosclerosis, Thrombosis, and Vascular Biology|May 16, 2015
Circulating Markers of Liver Function and Cardiovascular Disease RiskGiovanni Targher, Christopher D Byrne
Pageof 46

Showing results (11-20 of 458) with videos related to

Sort By:
Pageof 46
The Journal of Clinical Endocrinology and Metabolism|January 8, 2013
Clinical Review: Nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complicationsGiovanni Targher, Christopher D Byrne
Nature Reviews. Gastroenterology & Hepatology|June 30, 2016
Obesity: Metabolically healthy obesity and NAFLDGiovanni Targher, Christopher D Byrne
Endocrine|March 6, 2014
Lower 25-hydroxyvitamin D3 levels and increased risk of liver diseases: is there a causal link?Giovanni Targher, Christopher D Byrne
Metabolic Syndrome and Related Disorders|February 26, 2015
A Perspective on Metabolic Syndrome and Nonalcoholic Fatty Liver DiseaseGiovanni Targher, Christopher D Byrne
Hepatology (Baltimore, Md.)|August 3, 2018
Ad Libitum Mediterranean or Low-Fat Diets as Treatments for Nonalcoholic Fatty Liver Disease?Giovanni Targher, Christopher D Byrne
ACP Journal Club|January 20, 2005
Review: orlistat and sibutramine are modestly effective for weight loss at 1 yearChristopher D Byrne, Sarah Wild
Heart (British Cardiac Society)|May 16, 2008
Time to rethink high-density lipoprotein?Sarah Wild, Christopher D Byrne
Seminars in Thrombosis and Hemostasis|February 12, 2013
Diagnosis and management of nonalcoholic fatty liver disease and its hemostatic/thrombotic and vascular complicationsGiovanni Targher, Christopher D Byrne
Nature Reviews. Gastroenterology & Hepatology|November 20, 2019
What's new in NAFLD pathogenesis, biomarkers and treatment?Christopher D Byrne, Giovanni Targher
Arteriosclerosis, Thrombosis, and Vascular Biology|May 16, 2015
Circulating Markers of Liver Function and Cardiovascular Disease RiskGiovanni Targher, Christopher D Byrne
Pageof 46